Article
CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma.
Communications biology - 28 May 2024
Wang Li, Wen Xiaosha, Yang Yang, Hu Zheng, Jiang Jing, Duan Lili, Liao Xiaofen, He Yan, Liu Yaru, Wang Jing, Liang Zhikun, Zhu Xiaoya, Liu Quan, Liu Tiancai, Luo Dixian
Abstract excerpt
Despite recent technological advancements in cell tumor DNA (ctDNA) mutation detection, challenges persist in identifying low-frequency mutations due to inadequate sensitivity and coverage of current procedures. Herein, we introduce a super-sensitivity and specificity technique for detecting ctDNA mutations, named HiCASE. The method utilizes PCR-based CRISPR, coupled with the restriction enzyme. In this work,...
Topics
- Humans
- Circulating Tumor DNA
- Mutation
- ErbB Receptors
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- CRISPR-Cas Systems
- Sensitivity and Specificity
- DNA Mutational Analysis
- Female
- Male